Participated · Series A · Oct 2025

Founded in 2020 by Harvard Business School classmates Tina Keshani, Julia Cole, and Sophia Richter, Seven Starling delivers technology-enabled maternal mental-health care. Its platform combines clinical evaluations, medication management, and both individual and group therapy to treat depression, anxiety, and related conditions tied to parenthood. All services are covered by insurance, helping patients access support without prohibitive out-of-pocket costs. The company plans to use new capital to expand into a dozen additional states by the end of 2026. Seven Starling’s care model targets postpartum, infertility, miscarriage, and loss, aiming to close gaps in traditional maternal health services. To date, the startup has raised $21.8 million across three rounds, giving it resources to scale its virtual operations and provider network.

Participated · Series A · Jul 2024

Novocuff develops the Novocuff Cervical Control System (CCS), a medical device designed to stabilize and close the cervix to retain amniotic fluid and sustain cervical length with the goal of extending pregnancy. The company is focused on improving pregnancy outcomes and reducing preterm births caused by PPROM and cervical shortening. Novocuff says it aims to transform the standard of care and bring the device to global markets, including low- and middle-income countries. Proceeds from an oversubscribed $26 million Series A will fund team expansion, a U.S. multi-center pivotal clinical trial planned for early 2025, pursuit of marketing authorization, and early-stage commercialization. The company completed an initial $2 million seed round prior to the Series A and has added clinical hires Kathryn Wine (VP, Clinical Affairs) and Marissa VanDeVeer (Clinical Engineer). Novocuff frames its work against the global burden of preterm birth, citing WHO data that preterm complications caused roughly 1 million infant deaths in 2020.

Participated · Series A · Jun 2024

Raydiant Oximetry is a venture-backed, clinical-stage medical device company based in San Ramon, California, focused on improving outcomes for mothers and babies during childbirth. The company was founded by Neil P. Ray, MD, and has developed Lumerah™, a low-cost, non-invasive sensor that continuously monitors fetal oxygenation during labor, and Daisy™, a vacuum-induced surgical tool for OB/GYN applications. Raydiant’s core product work centers on fetal pulse oximetry to better identify fetal distress and potentially avoid medically unnecessary C-sections. The company plans to use prize funding and development sprints to further advance and de-risk its technologies for clinical adoption. Raydiant frames its innovations as transformative for monitoring practices during labor and delivery and is advancing through clinical-stage development and expert evaluation. Raydiant Oximetry, based in San Ramon, CA and founded by Neil P. Ray, develops two clinical-stage technologies: Lumerah™, a low-cost, non-invasive sensor that continuously monitors fetal oxygenation during labor, and Daisy™, a surgical device to quantify blood loss, treat uterine atony and prevent postpartum hemorrhage after C-section. The company is focused on improving outcomes for mothers and babies during childbirth. Raydiant plans to use its new funding to support two clinical studies of Lumerah and Daisy being conducted at Eastern Virginia Medical School under Dr. George Saade. The studies aim to generate clinical evidence to validate performance and safety in labor and delivery settings. Raydiant is pursuing regulatory and clinical pathways typical for medical devices as it advances these technologies through clinical evaluation. The company recently raised extension funding to advance those clinical programs. Raydiant Oximetry is a clinical-stage medical device company based in San Ramon, CA focused on improving women’s and neonatal health. Its core product is LUMERAH™, a non-invasive fetal oximeter designed to detect fetal distress during labor and delivery. LUMERAH is an investigational medical device and is not currently approved for commercial sale. The company is led by founder and CEO Neil Ray, MD. Raydiant raised $5M in a Series A2 financing and intends to use the funds to complete a clinical study at the University of Texas Medical Branch in Galveston. The UTMB study, with Dr. George Saade as principal investigator, is part of clinical research supported by the NIH Maternal‑Fetal‑Medicine Network to advance validation of the device. Raydiant Oximetry is a Mountain View, California medical device company that has developed a noninvasive fetal monitor to directly measure a baby’s oxygenation during pregnancy and childbirth. Founded in 2016 and led by CEO Dr. Neil P. Ray, the company is in residence at the Fogarty Institute for Innovation. It has demonstrated feasibility of the technology in pregnant women through an IRB‑approved study and validated results in animal models. Raydiant holds two issued patents protecting the core technology and expects up to ten more patents over the next 36 months. The company raised $1M in seed funding and intends to use the proceeds to build a subsequent prototype with improved accuracy and reliability.

Led · Seed · Mar 2023

Iron Health is a tech-enabled, virtual care partner built at Redesign Health that complements OB/GYNs by integrating primary, specialty, behavioral, and wellness care. The company uses a click-and-mortar hybrid model and a virtual network of multidisciplinary providers to provide faster access to primary and specialty care and to break down care silos. Each patient receives a dedicated Iron Health Care Team delivering primary care, behavioral health, and other services via virtual visits and direct messaging, creating a single medical home centered on OB/GYN care. Iron Health is launching services in direct partnership with OB/GYN practices and healthcare systems. The founding team has experience across clinical practice, health technology, patient engagement, and entrepreneurship. The company is partnering with March of Dimes for clinical expertise, research, educational content, and market reach to scale impact and address care gaps in women’s health. Iron Health announced a $4.5 million seed investment at launch to support its growth.